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Lombardy. The monthly cost in the ﬁ rst year was €1249 per person (77% attributable 
to HAs, 15% to pharmaceuticals and 8% to outpatient claims), decreasing to 
€309 in the following years (54% HAs, 31% pharmaceuticals, 16% outpatient).
CONCLUSIONS: This large study on the burden of AMI shows the epidemiologic,
economic and clinical impact of the disease. DENALI, with its large population 
followed over time is a powerful and dynamic tool for epidemiologic and health
economic research.
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OBJECTIVES: Acute coronary syndromes (ACS) are life-threatening disorders 
requiring intensive medical management or invasive cardiovascular procedures. CABG 
is an important therapeutic procedure among these patients. In Brazil almost 21,000 
CABG are performed in public hospitals costing the government R$7379.49 each in 
average. The aim of this study is to determine the direct medical costs of CABG among
different Brazilian regions in the private setting. METHODS: Retrospective single-
cohort study analyzed administrative claims data for patients with ACS submitted to 
CABG in 2007–2008. From a nationwide database with 1,801,344 people all the
patients with ACS submitted to CABG were selected. The patients were split according 
to the Brazilian geographical region where the procedure was performed. Student T 
test was used to compare the costs among three different regions. RESULTS: We 
identiﬁ ed 263 patients with ACS submitted to CABG. 67% of the procedures 
were performed in Southeast (SE) region, 25% in Middle West (MW) and 8% in the
south region. The average o SD, quartile 25%, median and 75% of the CABG cost 
of whole sample were R$15,849.72 o R$7,355.69, R$12,153.84, R$14,605.45 and
R$18,735.46, respectively. The same parameters for the SE, MW and S regions were,
respectively R$15,721.25oR$8,309.74, R$11,545.23, R$14,398.47 and R$18,657.87; 
R$16,744.15 o R$4,212.57, R$13,340.56, R$15,688.26 and R$19,325.96 and
R$14,035.03 o R$6,272.96, R$9,145.53, R$14,163.88 and R$17,103.31. There was 
no statistical difference among the different regions of Brazil of total CABG cost. There
was no statistical difference among the different regions and the total sample average.
CONCLUSIONS: The CABG average cost we found represent the average Brazilian
private setting health cost independent of the region studied. The average total CABG 
cost in the private setting is at least the double in relation to the average total CABG 
cost in the public setting.
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OBJECTIVES: Antiplatelet and antithrombotic therapies have long been the focus of 
extensive clinical and economic investigations. In many of these studies, the primary 
endpoint of analysis was the incidence of “major bleeding.” Unfortunately, major 
bleeding does not have a standard or universal deﬁ nition. Major cardiovascular studies 
such as GUSTO, CURE, TIMI and the International Society on Thrombosis and 
Haemostasis (ISTH) have each established deﬁ nitions that result in vastly different
outcomes. Additionally, none of the common deﬁ nitions were designed for patients
undergoing surgery as part of their care. Analyses that compare outcomes from mul-
tiple trials must carefully examine the deﬁ nitions used. METHODS: We analyzed the
effect of applying 6 major bleeding deﬁ nitions on the incidence and costs of care for 
acute coronary syndrome (ACS) patients undergoing coronary artery bypass graft 
surgery (CABG) in their index hospitalization in a previously developed database of 
ACS patients from 14 health systems across the United States. RESULTS: Our com-
parison found that application of the different deﬁ nitions could result in a large 
variance in the primary outcome of “major bleeding” with equal impact on the com-
parisons for the cost of care. The incidence of major bleeding varied by as much as
50% as did the cost of treatment. The data review included ACS patients who under-
went CABG between January 2005 and December 2006. CONCLUSIONS: Compar-
ing the incidence, impact and costs of treating major bleeding between various clinical 
trials requires a careful assessment of the deﬁ nitions used. Development of a single 
standard deﬁ nition of “major bleeding” for use in clinical and observational trials is
recommended.
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OBJECTIVES: Although ezetimbe/simvastatin (10/40 mg/day) combination therapy
may have a superior cholesterol-lowering proﬁ le and be more cost effective than statin 
monotherapy, recent data suggest an increased risk of cancer. We estimate the cost-
effectiveness of ezetimibe/simvastatin vs. simvastatin (40 mg/day) monotherapy, evalu-
ating the effect of this risk. METHODS: A Markov model, employing a 1-year cycle,
was employed to estimate the incremental cost, outcomes, and cost-effectiveness ratio
(ICER) over a 5-year time horizon. Efﬁ cacy data were obtained from the Simvastatin 
and Ezetimibe in Aortic Stenosis (SEAS) study, the Scandinavian Simvastatin Survival 
Study, and the Heart Protection Study. Costs were estimated from fee schedules,
diagnosis-related groups, and average wholesale prices. Utility weights were obtained 
from the peer-reviewed literature. All costs and outcomes after the ﬁ rst year were dis-
counted 3% annually in the base-case. Deterministic and probabilistic sensitivity 
analyses were conducted to evaluate the effect of parameter uncertainty and assump-
tions on the model results. A cost-effectiveness acceptability curve displays the prob-
ability that ezetimibe/simvastatin is cost effective. RESULTS: Ezetimibe/simvastatin 
was dominant (i.e., cost less, resulted in better outcomes) in the base-case scenario. 
For a 1 million-patient cohort, ezetimibe/simvastatin would cost $1,674,715,503 less 
than monotherapy and would result in 15,906 additional quality-adjusted life-years
(QALYs). One-way sensitivity analyses indicate that higher incidence of cancer, lower 
monotherapy costs, and higher risk of myocardial infarction (MI) reduce the cost-
effectiveness of ezetimibe/simvastatin substantially. According to probabilistic analy-
ses, ezetimibe/simvastatin is cost-effective at $50,000/QALY only 36.7% of the time; 
even at a willingness-to-pay of $100,000/QALY, ezetimibe/simvastatin is cost effective
less than 50% of the time. CONCLUSIONS: Although our study suggests that simv-
astatin/ezetemibe treatment is cost effective, policy makers should interpret these 
results in light of possible uncertainty surrounding the incidence of cancer, incidence
of myocardial infarction, and the true cost of simvastatin treatment following generic 
approval.
PCV72
COST-EFFECTIVENESS ANALYSIS OF ADD-ON ALISKIREN TO LOSARTAN 
TREATMENT FOR PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION
AND NEPHROPATHY IN THE CZECH PATIENTS FROM PAYOR
PERSPECTIVE
Kutscherauer P1, Kodym R2, Bartaskova D3
1Novartis Pharmaceuticals Corporation, Prague, Czech Republic, 2Novartis Pharmaceuticals 
Corporation, Prague 3, Czech Republic, 3Charles University, Prague, Czech Republic
OBJECTIVES: Persistent high blood pressure is one of the leading causes of microal-
buminuria and progression of nephropathy in patients with type 2 diabetes. A large
number of studies have shown effective reduction of microalbuminuria after antihy-
pertensive therapy and reducing progression of nephropathy to end-stage renal disease 
(ESRD). In the AVOID study aliskiren once daily as an add-on therapy provide a sig-
niﬁ cant additional reduction in proteinuria compared to losartan alone. The objective
of this model was to evaluate a long-term cost-utility of the two strategies. METHODS:
AVOID was a multinational, randomized, double-blind study to evaluate the possible
renoprotective effect of aliskiren in the primary endpoint – the change in the urinary
albumin to creatinine ratio (UACR) when added aliskiren to existing losartan and 
optimal antihypertensive therapy for six months in hypertensive patients with type 2 
diabetes and nephropathy. However the duration of this study was short to evaluate 
the incidence of ESRD. The AVOID cost-effectiveness Markov model is designed to 
estimate progression to ESRD using the primary endpoint of AVOID – superior reduc-
tion in UACR for aliskiren versus placebo – and project associated local costs and
clinical outcomes in Czech patients suffered by type 2 diabetes, hypertension and 
nephropathy. RESULTS: AVOID demonstrates that combination of aliskiren with
losartan showed systematically improved effectiveness compared with losartan 
alone. Effectiveness was expressed as QALY gained throughout the model time 
horizon. The incremental cost-effectiveness (ICER) of the aliskiren treatment in the
base case was below € 1027 per QALY gained and in the extended case improved
with real-life cost of dialysis and renal transplantation on cost-saving therapeutical
approach. CONCLUSIONS: Aliskiren once daily as add-on therapy to losartan is 
highly cost-effective option for hypertensive patients with type 2 diabetes and
nephropathy.
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OBJECTIVES: Regadenoson is a vasodilating stress agent used in patients undergoing
myocardial perfusion imaging (MPI) for detection of coronary artery disease. Its rapid
injection administration and weight-independent dosing may result in shortened
administration time versus adenosine or dipyridamole. We assessed whether the use 
of regadenoson results in overall MPI reduction in lab personnel time and consequen-
tially increased patient throughput. METHODS: An economic model was developed 
comparing regadenoson versus adenosine and dipyridamole on MPI laboratory pro-
ductivity and patient throughput through reduction in administration time and staff 
labor. We developed a pharmacologic stress agent survey (n  19) to evaluate the labo-
ratory personnel time and patient throughput. The results of this survey were used to 
populate the model. We included the administration of stress agents and managing 
associated adverse events for MPI. We solicited key opinion leaders including nurses, 
nuclear technologists and cardiologists to complete this survey in April and May of 
2008. RESULTS: Laboratory efﬁ ciency is reliant in part upon medication characteris-
tics (e.g. different stress agent dose, administration time, use of rapid injection vs. 
